Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2004;24:1886-1890
Published online before print July 29, 2004, doi: 10.1161/01.ATV.0000141045.49616.6f
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
24/10/1886    most recent
01.ATV.0000141045.49616.6fv1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Saiura, A.
Right arrow Articles by Makuuchi, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Saiura, A.
Right arrow Articles by Makuuchi, M.
Related Collections
Right arrow Gene therapy
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2004;24:1886.)
© 2004 American Heart Association, Inc.


Atherosclerosis and Lipoproteins

Antimonocyte Chemoattractant Protein-1 Gene Therapy Attenuates Graft Vasculopathy

Akio Saiura; Masataka Sata; Ken-ichi Hiasa; Shiro Kitamoto; Miwa Washida; Kensuke Egashira; Ryozo Nagai; Masatoshi Makuuchi

From the Departments of Surgery (A.S., M.M.) and Cardiovascular Medicine (M.S., M.W., R.N.), University of Tokyo, Graduate School of Medicine, Japan; and the Department of Cardiovascular Medicine (K.H., S.K., K.E.), University of Kyushu, Graduate School of Medicine, Fukuoka, Japan.

Correspondence to Dr Masataka Sata, Department of Cardiovascular Medicine, University of Tokyo Graduate School of Medicine, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. E-mail: msata-tky{at}umin.ac.jp

Objective— Accelerated coronary arteriosclerosis remains a major problem in the long-term survival of cardiac transplant recipients. However, the pathogenesis of graft vasculopathy is poorly understood, and there is no effective therapy. Transplant arteriosclerosis is characterized by early mononuclear cell attachment on the transplanted vessel followed by development of concentric neointimal hyperplasia. Early and persistent expression of monocyte chemoattractant protein-1 (MCP-1) in cardiac allografts has been implicated for the pathogenesis of transplant arteriosclerosis.

Methods and Results— We investigated whether anti-MCP-1 gene therapy can inhibit the development of intima hyperplasia in a mouse model of cardiac transplantation. Either the dominant-negative form of MCP-1 (7ND) or control vector was transfected into the skeletal muscles of B10.D2 mice. Cardiac allografts from DBA/2 mice were transplanted heterotopically into B10.D2 mice. 7ND gene transfer was associated with a significant reduction of the number of mononuclear cells accumulating in the lumen of the graft coronary arteries at 1 week and an attenuation of the development of the lesion at 8 weeks (intima/media ratio 0.79±0.05 versus 0.48±0.04).

Conclusions— The MCP-1/chemokine receptor 2 (CCR2) signaling pathway plays a critical role in the pathogenesis of graft vasculopathy. This new anti-MCP-1 gene therapy might be useful to treat graft vascular disease.

In a murine cardiac allograft model, the gene transfer of the dominant negative form of MCP-1 to the recipients significantly reduced the number of mononuclear cells accumulating in the luminal side of the graft coronary arteries at 1 week and attenuated the development of the lesion at 8 weeks.


Key Words: cardiac transplantation • graft arteriosclerosis • MCP-1 • CCR2 • chemokine




This article has been cited by other articles:


Home page
Eur. J. Cardiothorac. Surg.Home page
G. Vassalli, M.-E. Roehrich, P. Vogt, G. B. Pedrazzini, F. Siclari, T. Moccetti, and L. K. von Segesser
Modalities and future prospects of gene therapy in heart transplantation
Eur. J. Cardiothorac. Surg., June 1, 2009; 35(6): 1036 - 1044.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
A. Schober
Chemokines in Vascular Dysfunction and Remodeling
Arterioscler Thromb Vasc Biol, November 1, 2008; 28(11): 1950 - 1959.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
A. Schepers, D. Eefting, P.I. Bonta, J.M. Grimbergen, M.R. de Vries, V. van Weel, C.J. de Vries, K. Egashira, J.H. van Bockel, and P.H.A. Quax
Anti-MCP-1 Gene Therapy Inhibits Vascular Smooth Muscle Cells Proliferation and Attenuates Vein Graft Thickening Both In Vitro and In Vivo
Arterioscler Thromb Vasc Biol, September 1, 2006; 26(9): 2063 - 2069.
[Abstract] [Full Text] [PDF]